Abstract
Objective: Statins are the most prescribed lipid lowering agents and consequently they prevent obstructive cardiovascular events in the world. Severe adverse effects of statins, involving myopathy and hepatotoxicity, sometimes limit their usage as lipid lowering agents. We now investigate the toxicity of statins and prove the protective effect of quercetin against statins toxicity in cell line. Methods: Human hepatocellular carcinoma cells HepG2 were used in this study were cultured at 37℃ in 5% CO2, in Roswell Park Memorial Institute medium (RPMI 1640) and were supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin. HepG2 cells were cultured with some of statins as Atorvastatin, Simvastatin and Rosuvastatin with 10µM concentration with and without pretreatment with 10, 20, 40µM quercetin 4 hours before the addition of statins, then cell line was incubated for 24 and 48 hours. Toxicity of statins was determined by cell viability assay (MTT assay), ALT&AST level assay, lipid peroxidation assay by Malondialdehyde (MDA) and Immunofluorescence staining assay using DAPI. Results: ALT&AST levels were significantly increased after the addition of statins in HepG2 cells when compared with the control group (DMSO 0.1%), and ALT&AST levels were significantly decreased with pretreatment of the cells with quercetin 4 hours before the addition of statins in a dose-dependent manner when compared with statin group. Cell viability percentage (MTT concentration) was decreased significantly after the addition of statins to HepG2 cells when compared with the control group, and MTT concentration was significantly increased with pretreatment of the cells with quercetin 4 hours before the addition of statins in a dose-dependent manner when compared with statin group. MDA concentrations increased significantly after the addition of statins to HepG2 cells when compared with the control group, and decreased when the cells were pretreated with quercetin 4 hours before the addition of statins in a dose-dependent manner when compared with statin group. Statins cause cellular oxidative damage by liberating reactive oxygen species, and the cellular damage was prevented when the cells pretreated with quercetin 4 hours before addition of statins. Conclusions: We found that, quercetin shall protect HepG2 cells from statins-induced hepatotoxicity with 10, 20, 40µM concentrations without significant difference between 20 and 40µM concentrations, and may be developed as a therapeutic agent for possible statins toxicity.
Highlights
Statins (3-hydroxy-3-methylglutaryl co-enzyme-A reductase inhibitors) are the most prescribed agents and the first-line drugs for treatment of hyperlipidemia and they prevent obstructive cardiovascular events in the world
Atorvastatin group; consists of the following subgroups: a) HepG2 cells treated with 10 μM atorvastatin only (Toxic group). b) HepG2 cells treated with 10 μM atorvastatin + 10 μM quercetin. c) HepG2 cells treated with 10 μM atorvastatin + 20 μM quercetin. d) HepG2 cells treated with 10 μM atorvastatin + 40 μM quercetin
Rosuvastatin group; consists of the following subgroups: a) HepG2 cells treated with 10 μM rosuvastatin only (Toxic group). b) HepG2 cells treated with 10 μM rosuvastatin + 10 μM quercetin. c) HepG2 cells treated with 10 μM rosuvastatin + 20 μM quercetin. d) HepG2 cells treated with 10 μM rosuvastatin + 40 μM quercetin
Summary
Statins (3-hydroxy-3-methylglutaryl co-enzyme-A reductase inhibitors) are the most prescribed agents and the first-line drugs for treatment of hyperlipidemia and they prevent obstructive cardiovascular events in the world. These pharmaceuticals block the mevalonic acid pathway by inhibition of the rate limiting step in the hepatic de novo cholesterol biosynthesis. The present study focused on statin induced hepatotoxicity and possible hepatotoxicity mechanisms. Many observational studies in North America and Europe have confirmed that that statins increase liver enzymes, risk of myopathy, and risk of diabetes mellitus (Kubatka et al, 2014)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have